FDA authorizes booster dose of Pfizer vaccine for certain populations

The U.S. Food and Drug Administration has amended the emergency use authorization for the Pfizer COVID-19 vaccine to allow certain populations to receive a single booster dose.

The following populations can receive a booster dose at least six months after getting the initial two-dose vaccine:

  • People ages 65 and older
  • People ages 18 through 64 who are at high risk of severe COVID-19
  • People ages 18 through 64 whose frequent institutional or occupational exposure to SARS-CoV-2 puts them at high risk of serious complications of COVID-19 including severe COVID-19

This authorization only applies to the Pfizer-BioNTech COVID-19 vaccine.

Share this article: